LON:AREC Arecor Therapeutics Final Earnings Report GBX 64.49 +0.99 (+1.56%) As of 07:29 AM Eastern ProfileEarnings History Arecor Therapeutics EPS ResultsActual EPSGBX 2Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AArecor Therapeutics Revenue ResultsActual Revenue$1.71 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArecor Therapeutics Announcement DetailsQuarterFinalDate4/13/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Arecor Therapeutics Earnings HeadlinesArecor Therapeutics PLC Ordinary Shares 6UIJune 30, 2026 | morningstar.comMArecor Therapeutics CEO on advancing ultra-rapid insulin trial and oral GLP-1 - ICYMIApril 17, 2026 | proactiveinvestors.com.auThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.July 17 at 1:00 AM | Banyan Hill Publishing (Ad)Arecor targets broader AT278 partnership as phase II trial nearsApril 13, 2026 | uk.finance.yahoo.comArecor targets phase II trial for AT278 in 2026 - ICYMIFebruary 14, 2026 | uk.finance.yahoo.comArecor targets phase II insuling trial for 2026 after successful 2025February 11, 2026 | finance.yahoo.comSee More Arecor Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arecor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arecor Therapeutics and other key companies, straight to your email. Email Address About Arecor TherapeuticsArecor Therapeutics (LON:AREC) (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion-dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target.View Arecor Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Abbott Laboratories Stock Is Suddenly Winning Back Wall StreetRevving Up Returns: Big Banks Race Through the Rate PlateauWhy Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the TestAI’s Power Crunch Fuels a Pivot for These 2 Oilfield StocksToast’s Comeback Story Is Getting Harder for Wall Street to IgnoreWhy Conagra’s Dividend Cut Could Be the Best Thing for InvestorsWhich Storage Stock Is Best Positioned to Win the AI Memory War? Upcoming Earnings HDFC Bank (7/18/2026)ICICI Bank (7/18/2026)General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
